1124 related articles for article (PubMed ID: 16478899)
21. Effects of Nigella sativa oil with a low-calorie diet on cardiometabolic risk factors in obese women: a randomized controlled clinical trial.
Mahdavi R; Namazi N; Alizadeh M; Farajnia S
Food Funct; 2015 Jun; 6(6):2041-8. PubMed ID: 26029855
[TBL] [Abstract][Full Text] [Related]
22. What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management?
Jensen MD
Am J Med; 2007 Sep; 120(9 Suppl 1):S25-31; discussion S31-2. PubMed ID: 17720358
[TBL] [Abstract][Full Text] [Related]
23. Rimonabant for the treatment of overweight and obese people.
Burch J; McKenna C; Palmer S; Norman G; Glanville J; Sculpher M; Woolacott N
Health Technol Assess; 2009 Oct; 13 Suppl 3():13-22. PubMed ID: 19846024
[TBL] [Abstract][Full Text] [Related]
24. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
Chanoine JP; Hampl S; Jensen C; Boldrin M; Hauptman J
JAMA; 2005 Jun; 293(23):2873-83. PubMed ID: 15956632
[TBL] [Abstract][Full Text] [Related]
25. Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors.
Cox SL
Drugs Today (Barc); 2005 Aug; 41(8):499-508. PubMed ID: 16234873
[TBL] [Abstract][Full Text] [Related]
26. Rimonabant.
Henness S; Robinson DM; Lyseng-Williamson KA
Drugs; 2006; 66(16):2109-19; discussion 2120-1. PubMed ID: 17112304
[TBL] [Abstract][Full Text] [Related]
27. CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans.
Bergholm R; Sevastianova K; Santos A; Kotronen A; Urjansson M; Hakkarainen A; Lundbom J; Tiikkainen M; Rissanen A; Lundbom N; Yki-Järvinen H
Int J Obes (Lond); 2013 May; 37(5):699-703. PubMed ID: 22828945
[TBL] [Abstract][Full Text] [Related]
28. Rimonabant: new drug. Obesity: loss of a few kilos, many questions.
Prescrire Int; 2006 Aug; 15(84):123-6. PubMed ID: 16977739
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.
Florentin M; Kostapanos MS; Nakou ES; Elisaf M; Liberopoulos EN
J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):274-82. PubMed ID: 19724023
[TBL] [Abstract][Full Text] [Related]
30. Rimonabant: new data and emerging experience.
Wright SM; Dikkers C; Aronne LJ
Curr Atheroscler Rep; 2008 Feb; 10(1):71-8. PubMed ID: 18366988
[TBL] [Abstract][Full Text] [Related]
31. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
[TBL] [Abstract][Full Text] [Related]
32. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D; Abrahamsson N; Davies M; Hesse D; Greenway FL; Jensen C; Lingvay I; Mosenzon O; Rosenstock J; Rubio MA; Rudofsky G; Tadayon S; Wadden TA; Dicker D;
JAMA; 2021 Apr; 325(14):1414-1425. PubMed ID: 33755728
[TBL] [Abstract][Full Text] [Related]
33. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.
Aronne LJ; Tonstad S; Moreno M; Gantz I; Erondu N; Suryawanshi S; Molony C; Sieberts S; Nayee J; Meehan AG; Shapiro D; Heymsfield SB; Kaufman KD; Amatruda JM
Int J Obes (Lond); 2010 May; 34(5):919-35. PubMed ID: 20157323
[TBL] [Abstract][Full Text] [Related]
34. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial.
Soyka M; Koller G; Schmidt P; Lesch OM; Leweke M; Fehr C; Gann H; Mann KF;
J Clin Psychopharmacol; 2008 Jun; 28(3):317-24. PubMed ID: 18480689
[TBL] [Abstract][Full Text] [Related]
35. Zonisamide for weight loss in obese adults: a randomized controlled trial.
Gadde KM; Franciscy DM; Wagner HR; Krishnan KR
JAMA; 2003 Apr; 289(14):1820-5. PubMed ID: 12684361
[TBL] [Abstract][Full Text] [Related]
36. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Wadden TA; Bailey TS; Billings LK; Davies M; Frias JP; Koroleva A; Lingvay I; O'Neil PM; Rubino DM; Skovgaard D; Wallenstein SOR; Garvey WT;
JAMA; 2021 Apr; 325(14):1403-1413. PubMed ID: 33625476
[TBL] [Abstract][Full Text] [Related]
37. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
Anderson JW; Schwartz SM; Hauptman J; Boldrin M; Rossi M; Bansal V; Hale CA
Ann Pharmacother; 2006 Oct; 40(10):1717-23. PubMed ID: 16940406
[TBL] [Abstract][Full Text] [Related]
38. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
[TBL] [Abstract][Full Text] [Related]
39. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
Nissen SE; Wolski KE; Prcela L; Wadden T; Buse JB; Bakris G; Perez A; Smith SR
JAMA; 2016 Mar; 315(10):990-1004. PubMed ID: 26954408
[TBL] [Abstract][Full Text] [Related]
40. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.
Kakafika AI; Mikhailidis DP; Karagiannis A; Athyros VG
J Clin Pharmacol; 2007 May; 47(5):642-52. PubMed ID: 17392496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
